<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Extracted Document</title>
    <style>
        body { font-family: Arial, sans-serif; max-width: 900px; margin: 0 auto; padding: 20px; }
        h1, h2, h3 { color: #333; }
        .page { margin-bottom: 50px; border-bottom: 2px solid #ccc; padding-bottom: 30px; }
        .title { font-size: 1.3em; font-weight: bold; margin: 20px 0; }
        .text { margin: 15px 0; line-height: 1.6; }
        .figure { margin: 20px 0; text-align: center; }
        .figure img { max-width: 100%; height: auto; border: 1px solid #ddd; }
        .figure-caption { font-style: italic; color: #666; margin-top: 10px; }
        .metadata { background: #f5f5f5; padding: 15px; margin-top: 30px; }
    </style>
</head>
<body>

<h1>Extracted Document</h1>
<p><strong>Source:</strong> data/clinical_files/Liu et al. (2024).pdf</p>
<p><strong>Total Pages:</strong> 13</p>
<hr>
<div class="page">
<h2>Page 1</h2>
<div class="title">year 1, but there was no signiﬁcant difference in HA stalk antibody fold rise
among vaccine groups in either year 1 or year 2. Multiple seasons of non-eg
based vaccination may be needed to redirect antibody responses from
immune memory to egg-adapted epitopes and re-focus the immune respons
towards epitopes on the circulating viruses to improve vaccine effectivenes
Inﬂuenza viruses are a common cause of respiratory infections in
humans, annual inﬂuenza vaccination has been recommended in the
manufacturing process can lead to egg-adapted mutations in t
hemagglutinin (HA) protein in IIV, that could result in altered an</div>
<div class="text">p<br>g<br>p<br>mbinant or cell culture-based<br>ed inﬂuenza vaccines<br>Feng Liu<br>1, F. Liaini Gross1, Sneha Joshi1, Manjusha Gaglani<br>2,3,4,<br>Allison L. Naleway5, Kempapura Murthy4, Holly C. Groom5, Meredith G. Wesley1,6<br>Laura J. Edwards6, Lauren Grant1, Sara S. Kim1, Suryaprakash Sambhara1,<br>Shivaprakash Gangappa<br>1, Terrence Tumpey1, Mark G. Thompson1,<br>Alicia M. Fry1, Brendan Flannery<br>1, Fatimah S. Dawood1 & Min Z. Levine<br>1<br>Repeat vaccination with egg-based inﬂuenza vaccines could preferentially<br>boost antibodies targeting the egg-adapted epitopes and reduce immuno-<br>genicity to circulating viruses. In this randomized trial (Clinicaltrials.gov:<br>NCT03722589), sera pre- and post-vaccination with quadrivalent inactivated<br>egg-based (IIV4), cell culture-based (ccIIV4), and recombinant (RIV4) inﬂuenza<br>vaccines were collected from healthcare personnel (18-64 years) in 2018−19<br>(N = 723) and 2019−20 (N = 684) inﬂuenza seasons We performed an</div>
<div class="text">Article<br>Redirecting antibody</div>
<div class="text">https://doi.org/10.1038/s41467-023-44551-x<br>esponses from egg-</div>
</div>
<div class="page">
<h2>Page 2</h2>
<div class="text">(<br>)<br>IIV4-ccIIV4<br>n=106 (*51)<br>IIV4-RIV4<br>n=104 (*44)<br>IIV4-IIV4<br>n=103 (*41)<br>Excluded n=5<br>Did not meet per protocol criteria<br>Fig. 1 | CONSORT diagrams for screening and Enrollment of participants in Year<br>1 (2018−2019) and Year 2 (2019−2020). Abbreviations: IIV4: Inactivated inﬂuenza<br>vaccine (Fluzone® or Fluarix® Quadrivalent); ccIIV4: Cell-culture based IIV</div>
<div class="text">during the preceding ﬁve seasons.<br>Year 1 (2018-20<br>ccIIV4 n=283<br>18-44 years: n=135<br>45-64 years: n=148 <br>Completed day 0 (n=283)<br>1 month (n=280) and <br>6 months (n=266) visit<br>RIV n=198<br>18-44 years: n=99<br>45-64 years: n=99<br>Completed day 0 (n=19<br>1 month (n=196) and <br>6 months (n=177) visit<br>Year 2: Year 1 participant<br>IIV4 in Year 1<br>n=318 (*139)<br>Re-randomized to ccIIV4, RIV4, or IIV4<br>n=318 (*139)<br>Year 1: 2018-2019<br>Year 2: 2019-2020</div>
<div class="figure">
<img src="figures/figure_p2_4ccead8c.png" alt="[FIGURE 3 - See figure_p2_4ccead8c.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 3 - See figure_p2_4ccead8c.png]</div>
</div>
<div class="text">a cell culture based inﬂuenza vaccine (Flucelvax Quadrivalent<br>by<br>Seqirus, Inc., ccIIV4) and a recombinant inﬂuenza vaccine (Flublok<br>Quadrivalent® by SanoﬁPasteur RIV4) RIV4 contains 3 times the</div>
<div class="text">RIV4-RIV4<br>n=74<br>ccIIV4-RIV4<br>n=106<br>ccIIV4-ccIIV4<br>n=101<br>RIV4-ccIIV4<br>n=73<br>Excluded n=12<br>Did not meet per protocol criteria<br>(Flucelvax® Quadrivalent); RIV4: recombinant-hemagglutinin inﬂuenza vaccine<br>(Flublok® Quadrivalent). *Numbers in parenthesis are new enrollees for Year 2.</div>
<div class="title">None</div>
<div class="text">sas/14/2017 (H3N2) like virus respectively while the B/Victoria and B/<br>Yamagata components remained the same (Table 1).<br>Enrolled and Randomized n=723<br>accine Allocation<br>Fluzone IIV4 n=122<br>18-44 years: n=57<br>45-64 years: n=65<br>Completed day 0 (n=110)<br>1 month (n=110) and <br>6 months (n=101) visit<br>Fluarix IIV4 n=120<br>18-44 years: n=55<br>45-64 years: n=65<br>Completed day 0 (n=120)<br>1 month (n=118) and <br>6 months (n=107) visit <br>e-enrolled in Year 2 and new enrollees randomized n=684 (139*)<br>ccIIV4 in Year 1<br>n=214<br>RIV4 in Year 1<br>n=152</div>
</div>
<div class="page">
<h2>Page 3</h2>
<div class="text">motif at HA position 197; whereas egg-based B/Yamagata vaccine had<br>antibody responses to both egg- (GMT 122) and cell- (GMT 137</div>
<div class="figure">
<img src="figures/table_p3_a86abc54.png" alt="[TABLE 2 - See table_p3_a86abc54.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 2 - See table_p3_a86abc54.png]</div>
</div>
<div class="text">Year 2<br>A/Kansas/14/2017 cell a,d<br>N<br>N<br>A<br>S<br>G<br>K<br>N(CHO-)<br>S<br>K<br>N<br>A/Kansas/14/2017 egg b<br>N<br>N<br>A<br>S<br>G<br>K<br>N(CHO-)<br>S<br>K<br>N<br>B/Victoria lineage<br>129<br>197<br>199<br>Year 1<br>& 2<br>B/Colorado/06/2017 cell<br>G<br>N<br>T<br>B/Colorado/06/2017 egg<br>G<br>T(CHO-)<br>T<br>B/Maryland/15/2016 BX-69A egg CVV<br>D<br>N(CHO-)<br>I</div>
<div class="title">A/Singapore/INFIMH-16-0019/2016 NIB-104
egg CVV (EPI1151864) c
S
K
T</div>
<div class="text">the study<br>Viruses<br>Amino acids difference<br>A(H1N1)pdm09<br>45<br>74<br>120<br>Year 1<br>A/Michigan/45/2015 cell a<br>R<br>S<br>T<br>A/Michigan/45/2015 egg<br>R<br>S<br>T<br>A/Michigan/45/2015 X-275 egg CVV<br>(EPI830246) b<br>R<br>S<br>T<br>A/Singapore/GP1908/2015 IVR-180 egg<br>CVV (EPI848715) c,d<br>R<br>S<br>A<br>Year 2<br>A/Idaho/07/2018 cell a,d<br>R<br>R<br>T<br>A/Brisbane/02/2018 egg b<br>G<br>R<br>T<br>A(H3N2)<br>91<br>121<br>128<br>Year 1<br>A/Singapore/INFIMH-16-0019/2016 cell a<br>S<br>K<br>T<br>A/Singapore/INFIMH-16-0019/2016 egg<br>S<br>K<br>T<br>A/Singapore/INFIMH-16-0019/2016 IVR-186<br>egg CVV (EPI1082512) b<br>S<br>K<br>T</div>
<div class="text">A<br>G<br>S<br>N(CHO-)<br>Y<br>K<br>K<br>D<br>F<br>P<br>G<br>N<br>H</div>
<div class="title">A
G
S
N(CHO-)
Y
K
K
D
F
P
D/G¶
N
H
A
G
S
N(CHO )
Y
K
K
D
F
P
G
N
H</div>
<div class="text">on the HA head domain<br>164<br>183<br>209<br>223<br>225<br>282<br>295<br>298<br>S<br>S<br>K<br>Q<br>G<br>P<br>I<br>I<br>S<br>S<br>K<br>R<br>G<br>P<br>I<br>I<br>S<br>S<br>M<br>R<br>G<br>P<br>I<br>I<br>S<br>S<br>K<br>Q<br>A<br>P<br>I<br>I<br>T<br>P<br>K<br>Q<br>G<br>P<br>V<br>I<br>T<br>P<br>K<br>R<br>G<br>A<br>V<br>V<br>138<br>142<br>144<br>158<br>159<br>160<br>171<br>190<br>193<br>194<br>225<br>246<br>311<br>A<br>G<br>S<br>N(CHO)<br>Y<br>T<br>K<br>D<br>F<br>L<br>D<br>N<br>H</div>
</div>
<div class="page">
<h2>Page 4</h2>
<div class="figure">
<img src="figures/figure_p4_5bf4bc66.png" alt="[FIGURE 1 - See figure_p4_5bf4bc66.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p4_5bf4bc66.png]</div>
</div>
<div class="text">Day 0<br>1 m<br>6 m<br>5<br>10<br>H<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>Fig. 2 | MN or HI Antibody responses to egg- and cell-propagated vaccine<br>viruses at pre-vaccination (Day 0), 1-month, and 6-months post-vaccination in<br>Year 1. Antibody titers from each of the four vaccine groups were presented as<br>geometric mean titers (GMTs) with 95% conﬁdence interval (CI) respectively for<br>18−44 years and 45−64 years age groups. Gray dots represented individual titers.<br>Fluzone IIV4 18−44 years: Day 0 (n = 52), 1 m (n = 52), 6 m (n = 47); Fluzone IIV4 45-<br>64 years: Day 0 (n = 58), 1 m (n = 58), 6 m (n = 54); Fluarix IIV4 18−44 years: Day 0</div>
<div class="text">B/VIC<br>B/YAM<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>HI titer<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>ers (Log2 scale)<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.035<br>0.019<br>0</div>
<div class="text">A(H3N2)<br>A(H1N1)pdm09<br>18-44 yrs egg virus<br>18-44 yrs cell virus<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>MN titers (Log2 scale)<br>0.003<br>0.014<br><0.0001<br>0.0008<br>0.044<br><0.0001<br>Day 0<br>1 m<br>6<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.0024<br><0.0001<br><0.0001<br>0.008<br>0<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>(Log2 scale)<br>0.02<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.003</div>
<div class="text">Day 0<br>1 m<br>6 m<br>Day 0<br>1 m<br>6 m<br>ccIIV4 45−64 years: Day 0 (n = 148), 1 m (n = 147), 6 m (n = 142); RIV4 18−44 years:<br>Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45−64 years: Day 0 (n = 98), 1 m<br>(n = 98), 6 m (n = 92); Microneutralization titers (MN) were measured for A(H3N2)<br>virus, while hemagglutination inhibition (HI) titers were measured for A(H1N1)<br>pdm09, B/Victoria (B/VIC), and B/Yamagata (B/YAM) viruses. One-way ANOVA<br>corrected for multiple comparisons (Tukey’s test) was used to compare the GMTs<br>of each time point among the 4 vaccine groups. Statistically signiﬁcant differences</div>
<div class="text">Day 0<br>1 m<br>6 m<br>Day 0<br>1 m<br>6 m<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.018<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120</div>
<div class="text">45-64 yrs egg virus<br>45-64 yrs cell virus<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.045<br>0.0046<br><0.0001<br>0.03<br>0.0074<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br><0.0001<br><0.0001<br><0.0001<br><0.0001<br><0.0001<br>0.004<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.0041<br>0.0072<br>Day 0<br>1 m<br>6 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.032<br>0.0009<br>0.0165<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120</div>
</div>
<div class="page">
<h2>Page 5</h2>
<div class="figure">
<img src="figures/figure_p5_f46cac45.png" alt="[FIGURE 1 - See figure_p5_f46cac45.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p5_f46cac45.png]</div>
</div>
<div class="text">Antibody responses to egg-adapted epitopes measured by<br>antibody GMT egg/cell titer ratio in year 1<br>To assess the levels of antibody responses targeting the egg-adapted<br>epitopes, we used the antibody “GMT egg/cell titer ratio” as a proxy to<br>quantify the extent of difference in antibody responses to egg- versus</div>
<div class="text">year 1, a total of 26 breakthrough infection cases were identiﬁed with</div>
<div class="text">Pre-existing A(H3N2) and A(H1N1)pdm09 HA stalk antibodies<br>were detected in participants at varies levels. Comparing HA stalk<br>antibody titers at 1-month post-vaccination versus day 0, vaccination<br>signiﬁcantly boosted A(H1N1)pdm09 HA stalk antibodies in all 4 vac<br>cine groups (p < 0.01), and signiﬁcantly boosted A(H3N2) HA stalk<br>antibodies in 3 of the 4 vaccine groups (p < 0.001, Fluzone IIV4, ccIIV4<br>and RIV4) (Fig. 4C). The RIV4 group had the highest A(H1N1)pdm09 HA<br>stalk and A(H3N2) HA stalk antibodies at 1-month post-vaccination<br>however the fold rises of HA stalk antibodies were low (<1.8) and<br>similar among all 4 vaccine groups (Fig. 4D). At 6-months post-vacci<br>nation, waning of HA stalk antibodies were more notable in ccIIV4 and</div>
<div class="text">(n = 98)) age groups respectively (A, B). Antibody waning was expressed as the GM<br>fold-reduction of titers from 1-month to 6-months (1 m/6 m) post-vaccination for</div>
<div class="title">groups were calculated for egg- and cell-propagated vaccine viruses, and for 18
years (Fluzone IIV4 (n = 52), Fluarix IIV4 (n = 55), ccIIV4 (n = 133), RIV4 (n = 98))</div>
<div class="text">0<br>1<br>2<br>3<br>4<br>5<br>6<br>0.0058<br>0.0088<br>0.0001<br><0.0001<br><0.0001<br><0.0001<br><0.0001<br>0.0006<br>0.021<br>0.047<br>0.034<br>0.004<br>0.005<br>0.0035<br>0.017<br>0.0003<br>0.024<br>0.01<br>0<br>1<br>2<br>3<br>4<br>5<br>6<br>45-64 years<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>0.0021<br>0.0006<br><0.0001<br><0.0001<br><0.0001<br><0.0001<br>0.015<br>0.0023<br>0.0019<br>0.002<br>0.039<br>0.043<br>0.0004<br>0.03<br>Geometric mean fold rise of antibody titers 1-month <br>post-vaccination (95%CI)<br>H3N2 egg<br>H3N2 cell<br>H1N1 egg<br>H1N1 cell<br>B/VIC egg<br>B/VIC cell<br>B/YAM cell<br>B/YAM egg<br>H3N2 egg<br>H3N2 cell<br>H1N1 egg<br>H1N1 cell<br>B/VIC egg<br>B/VIC cell<br>B/YAM cell<br>B/YAM egg<br>A<br>B<br>Fig. 3 | Fold rise of MN or HI antibody titers at 1-month post-vaccination and<br>waning of antibody titers at 6-months post-vaccination in Year 1. Geometric<br>mean (GM) fold rise of antibody titers (1 m/Day 0) from each of the four vaccine</div>
<div class="text">Fl<br>IIV4<br>1 month-fold rise (1m/Day 0)</div>
<div class="text">participants had GMT egg/cell ratio ≥4 to A(H3N2) and B/Victoria<br>viruses, suggesting a high prevalence of pre-existing neutralizing<br>antibodies targeting HA egg-adapted epitopes in this highly vaccinated<br>HCP population. After vaccination, in both age groups, the two egg-<br>based<br>vaccines<br>generally<br>reinforced<br>the<br>neutralizing<br>antibody<br>responses to egg-adapted epitopes as evidenced by an increased trend<br>in the proportion of participants with GMT egg/cell titer ratio ≥4. In<br>contrast, among RIV4 and ccIIV4 recipients, the proportion of parti-</div>
<div class="text">RIV4 recipients from the 45−64 years group (Fig. 5B).<br>Next, to assess whether vaccination with non-egg-based vaccines<br>can overcome the impact of egg-adaptation and reduce the GMT egg/<br>cell ratio in the vaccine responses, we calculated the “proportion of the<br>participants with egg/cell ratio ≥4” in MN/HI titers at pre- and 1-month<br>post-vaccination (Fig. 5C, D). At pre-vaccination, there was no sig-</div>
<div class="text">A(H1N1)pdm09 and B/Yamagata, the post-vaccination HI antibody<br>GMT egg/cell titer ratios were all <2 and similar (p > 0.05) among the<br>vaccine groups (Fig. 5A, B). For B/Victoria, the post-vaccination HI GMT<br>egg/cell titer ratios were slightly elevated (range: 2−3) with the ratio in<br>Fluzone IIV4 recipients signiﬁcantly higher (p < 0.05) than those in<br>0<br>1<br>0<br>1<br>2<br>3<br>4<br>45-64 years<br>0.002<br>0.003<br>0.036<br>0.002<br>0.0002<br><0.0001<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>Geometric mean fold reduction of antibody tit<br>post-vaccination (95%CI)<br>H3N2 egg<br>H3N2 cell<br>H1N1 egg<br>H1N1 cell<br>B/VIC egg<br>B/VIC cell<br>B/YAM cell<br>B/YAM egg<br>B/YAM egg<br>H3N2 egg<br>H3N2 cell<br>H1N1 egg<br>H1N1 cell<br>B/VIC egg<br>B/VIC cell<br>B/YAM cell<br>D<br>18−44 years (Fluzone IIV4 (n = 47), Fluarix IIV4 (n = 48), ccIIV4 (n = 124), RIV4<br>(n = 85)) and 45−64 years (Fluzone IIV4 (n = 54), Fluarix IIV4 (n = 59), ccIIV4<br>(n = 142), RIV4 (n = 92)) respectively (C, D). MN titers were measured for A(H3N2)<br>virus, while HI titers were measured for A(H1N1)pdm09, B/VIC, and B/YAM viruses.<br>One-way ANOVA corrected for multiple comparisons (Tukey’s test) was used to<br>compare the GM fold-rise or fold-reduction of each time point among the 4 vaccine<br>groups. Statistically signiﬁcant differences between groups are indicated by p<br>values on the horizontal bars.</div>
<div class="text">2<br>3<br>4<br>18-44 years<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>0.049<br>0.015<br>0.03<br>Waning-6 month-fold reduction (1m/6m)<br>ers 6 month <br>C</div>
</div>
<div class="page">
<h2>Page 6</h2>
<div class="figure">
<img src="figures/figure_p6_4ac7b207.png" alt="[FIGURE 1 - See figure_p6_4ac7b207.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p6_4ac7b207.png]</div>
</div>
<div class="text">(n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0<br>(n = 40), 1 m (n = 40), 6 m (n = 38). A: HA (A(H1N1)pdm09) or HA head (A(H3N2), B/</div>
<div class="text">Fig. 4 | Total HA binding antibody and HA stalk antibody responses measured<br>by ELISA at pre-vaccination (Day 0), 1-month, and 6-months post-vaccination<br>in Year 1. Antibody titers from each of the four vaccine groups were presented as<br>geometric mean titers (GMTs) with 95% conﬁdence interval (CI) for combined<br>18−44 years and 45−64 years age groups. Gray dots represented individual titers.<br>Fluzone IIV4: Day0 (n = 24), 1 m (n = 24), 6 m (n = 21); Fluarix IIV4: Day 0 (n = 24), 1 m</div>
<div class="text">ELISA titers<br>Day 0<br>1 m<br>6 m<br>400<br>800<br>1600<br>3200<br>Day 0<br>1<br>400<br>800<br>1600<br>3200</div>
<div class="text">ELIS<br>e)<br>Day 0<br>1 m<br>6 m<br>400<br>800<br>Day 0<br>1 m<br>400<br>51200<br><0.0001<br><0.0001<br>0.0011<br>0.0008<br>0.0002<br><0.0001<br>0.0081<br>0.018<br><0.0001<br>51200<br><0.0001<br><0.0001<br>0.005<br>0.004<br><0.0001<br><0.0001<br><</div>
<div class="title">B/VIC
ers (Log2 scale
3200
6400
12800
25600
51200
3200
6400
12800
25600</div>
<div class="text">ELISA tit<br>)<br>Day 0<br>1 m<br>6 m<br>400<br>800<br>1600<br>Day 0<br>1 m<br>400<br>800<br>1600<br>51200<br>0.019<br><0.0001<br><0.0001<br>0.0088<br>0.0004<br>0.0007<br>0.036<br>0.015<br>51200<br>0.0011<br><0.0001<br>0.0011<br>0.005<br>0.02<br><</div>
<div class="text">A(H3N2)<br>A(H1N1)pdm09<br>Egg virus HA<br>Cell vir<br>ELISA titers (Log2 scale)<br>ers (Log2 scale)<br>A<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>51200<br>0.006<br><0.000<br><0.00<br>3200<br>6400<br>12800<br>25600<br>51200<br>0.047<br>0.0001<br>0.0065<br><0.0001<br>0.014<br><0.0001<br>0.0082<br><0.0001<br>0.0028<br>0.0055<br>0.0004<br>0.03<br>3200<br>6400<br>12800<br>25600<br>51200<br>0.0063<br>0.0011<br>0.0066<br><0.00<br>0.01<br><0.<br>Day 0<br>1 m<br>6 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>51200<br>0.047<br>0.0037<br>0.032<br>0.032<br>0.002<br>0.013<br>0.014</div>
<div class="text">0<br>1<br>Geome<br>ELISA tite<br>H3 stalk<br>H1 stalk<br>6 m<br>corrected for multiple comparisons (Tukey’s test) was used to compare the GMTs<br>of each time point among the 4 vaccine groups (A, C). One-way ANOVA nonpara-<br>metric Kruskal-Wallis test was used to compare the fold changes among the 4<br>vaccine groups (B, D). Statistically signiﬁcant differences between groups are<br>indicated by p values on the horizontal bars.*: In (C), paired t test (two-tailed) was<br>used for comparing the pre- and 1 m post-vaccination stalk antibody titers within<br>the same vaccine group: signiﬁcantly higher HA stalk antibody titers were detected<br>in 1 m post-vaccination than pre-vaccination for H3 stalk binding antibody in Flu-<br>IIV4 (<br>0 0009)<br>IIV4 (<br>0 0004) RIV4 (<br>0 0001)<br>d f<br>H1 t lk</div>
<div class="text">Day 0<br>1 m<br>6 m<br>200<br>400<br>800<br>1600<br>3200<br>6400<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>0.02<br>0.043<br>0.0046<br>0.007<br>0.038<br><0.000<br>1<br>0.044<br>*<br>*<br>*<br>Day 0<br>1 m<br>6 m<br>200<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>0.0036<br><0.0001<br>0.03<br>0.0003<br>0.0017<br><0.0001<br>0.016<br><0.0001<br>0.0063<br>0.024<br>*<br>*<br>*<br>*<br>4<br>G<br>C<br>ELISA titers (Log2 scale)<br>ELISA titers (Log2 scale)<br>rise of  <br>(95% CI)<br>H3 stalk<br>H1 stalk<br>D<br>6 m<br>0.049<br>0.015<br>6 m<br>0.0016<br>0.0039<br><0.0001<br>0.0003<br>HA stalk ELISA titer fold-rise <br>(1m/day0)</div>
<div class="text">A<br>Geometric mean ratio of  ELISA <br>titer egg/cell HA (95% CI)<br>B<br>H3 HA<br>H1 HA<br>B/VIC HA<br>B/YAM HA<br>6 m<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>02<br><0.0001<br>0.0002<br>0<br>1<br>2<br>3<br>4<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>0.009<br><0.0001<br><0.0001<br>0.002<br>0.041<br>0.03<br>0.006<br>0.016<br>Egg/Cell HA ELISA titer ratio (1m)</div>
</div>
<div class="page">
<h2>Page 7</h2>
<div class="figure">
<img src="figures/figure_p7_4b113d40.png" alt="[FIGURE 1 - See figure_p7_4b113d40.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p7_4b113d40.png]</div>
</div>
<div class="text">A(H3N2) and B/VIC in the 18−44 years group, B/VIC virus and B/YAM<br>virus in the 45−64 years group, suggesting repeated boost to anti<br>bodies targeting egg-adapted epitopes in these participants after<br>receiving consecutive egg-based IIV4 vaccination. In contrast, among<br>recipients of non-egg-based vaccines in just one study year (IIV4-ccIIV4<br>or IIV4-RIV4) or in both study years (ccIIV4-ccIIV4, ccIIV4-RIV4, RIV4<br>ccIIV4, RIV4-RIV4), the proportions of participants with egg/cell ratio<br>each vaccine group. Proportions of participants who had ≥4 -fold reduced titer to</div>
<div class="text">A(H3N2)<br>A(H1N1)pdm09<br>B/VIC<br>B/YAM<br> f<br>o<br> <br>oit<br>a<br>r <br>n<br>a<br>e<br>m<br> cirt<br>e<br>m<br>o<br>e<br>G<br>B<br>0<br>1<br>2<br>3<br>4<br>5<br>6<br>45-64 years<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br><0.0001<br><0.0001<br>0.0084<br>0.011<br>Fig. 5 | Difference in MN or HI antibody responses to egg-adapted epitopes<br>stratiﬁed by age groups and vaccine type in Year 1. A, B: Geometric mean ratio<br>of egg/cell virus titers at 1-month post-vaccination with 95% CI for each vaccine<br>component among the 4 vaccine groups for 18-44 years (A Fluzone IIV4: n = 52,<br>Fluarix IIV4: n = 55, ccIIV4: n = 133, RIV4: n = 98) and 45−64 years (B Fluzone IIV4:<br>n = 58, Fluarix IIV4: n = 63, ccIIV4: n = 147, RIV4: n = 98) age groups. One-way<br>ANOVA nonparametric Kruskal-Wallis test was used for comparison of geometric</div>
<div class="text">A(H3N2)<br>A(H1N1)pdm09<br>B/VIC<br>B/YAM<br>)I<br>C<br> <br>%<br>5<br>9<br>( r<br>e<br>tit s<br>u<br>riv lle<br>c/<br>g<br>g<br>A<br>0<br>1<br>2<br>3<br>4<br>5<br>6<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>0.0014<br>0.0021<br>0.03</div>
<div class="text">Comparing pre- and 1-month post-vaccination, A(H3N2) HA stalk<br>binding antibodies were signiﬁcantly boosted in ccIIV4-RIV4, RIV4-RIV4,<br>IIV4-ccIIV4, and IIV4-RIV4 arms, while A(H1N1)pdm09 HA stalk binding<br>antibodies were also signiﬁcantly boosted in ccIIV4-ccIIV4 and RIV4-ccIIV4<br>arms (Fig. 8C). However, fold rise in both A(H1N1)pdm09 HA stalk and<br>A(H3N2) HA stalk antibodies were low (GM fold rise <1.78) with no sig-<br>niﬁcant difference (p > 0 05) among all 7 repeat vaccination arms (Fig 8D)<br>tion (C, D).</div>
<div class="text">cell vaccine virus (egg/cell titer ratio) at pre- and 1-month post-vaccination were<br>presented for each vaccine component among the 4 vaccine groups for 18−44<br>years (C) and 45−64 years (D). Fisher’s exact test (two-tailed) was performed for<br>comparing proportions of ≥4 -fold reduced titer to cell vaccine virus between pre-<br>and 1-month post-vaccination in each vaccine group. MN titers were measured for<br>A(H3N2) virus, while HI titers were measured for A(H1N1)pdm09, B/VIC, and B/<br>YAM viruses. Statistically signiﬁcant differences between groups are indicated by p</div>
<div class="text">0<br>Proportion of ≥4 -fold reduced titer to cell va<br>20<br>40<br>60<br>80<br>100<br>40%<br>21%<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>A(H3N2)<br>A(H1N1)pdm09<br>B/VIC<br>B/YAM<br>Pre<br>Post<br>Pre<br>Post<br>Pre<br>Post<br>Pre<br>Post<br>45-64 years<br>D<br>p=0.005</div>
<div class="text">20<br>40<br>60<br>80<br>100<br>58%<br>26%<br>Fluzone IIV4<br>Fluarix IIV4<br>ccIIV4<br>RIV4<br>ccine virus (egg/cell)<br>p=0.0001<br>A(H3N2)<br>A(H1N1)pdm09<br>B/VIC<br>B/YAM<br>18-44 years</div>
</div>
<div class="page">
<h2>Page 8</h2>
<div class="figure">
<img src="figures/figure_p8_e7b54fd7.png" alt="[FIGURE 1 - See figure_p8_e7b54fd7.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p8_e7b54fd7.png]</div>
</div>
<div class="text">g. 6 |<br>a t body espo ses to egg a d ce<br>p opagated vacc<br>e v uses at<br>pre- and 1-month post-vaccination in year 2 stratiﬁed by 7 repeat<br>vaccination arms. HI antibody titers from each of the 7 repeat vaccine arms were<br>presented as geometric mean titers (GMTs) with 95% conﬁdence interval (CI)<br>respectively for 18−44 years and 45−64 years age groups. Gray dots represented<br>individual titers 18−44 years: ccIIV4-ccIIV4 (n = 42) ccIIV4-RIV4 (n = 45) RIV4-</div>
<div class="text">B/VIC<br>B/YAM<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>0.014<br>0.0003<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.006<br>0.0004<br>0.0004</div>
<div class="text">A(H3N2)<br>A(H1N1)pdm09<br>18-44 yrs egg virus<br>18-44 yrs cell virus<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br><0.0001<br>0.011<br>0.013<br><0.0001<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.02<br>0.0011</div>
<div class="text">(n<br>45), RIV4 RIV4 (n<br>44), IIV4 ccIIV4 (n<br>57), IIV4 RIV4 (n<br>56), IIV4 IIV4 (n<br>56).<br>Unpaired t test (two-tailed) was used to compare the post-vaccination GMTs to cell<br>vaccine viruses between IIV4-IIV4 (Fluzone) arm and each of the remaining 6 vac-<br>cine arms within the same age group. Statistically signiﬁcant differences between<br>groups are indicated by p values on the horizontal bars.</div>
<div class="text">Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br><0.0001<br>0.007<br>0.0006<br><0.0001</div>
<div class="text">Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.01<br>0.004<br>0.01<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>0.04<br><0.0001<br>0.0006<br><0.0001<br>0.03<br>0.0002</div>
<div class="text">45-64 yrs egg virus<br>45-64 yrs cell virus<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>HI titers (Log2 scale)<br>Day 0<br>1 m<br>5<br>10<br>20<br>40<br>80<br>160<br>320<br>640<br>1280<br>2560<br>5120<br>ccIIV4-ccIIV4<br>ccIIV4-RIV4<br>RIV4-ccIIV4<br>RIV4-RIV4<br>IIV4-ccIIV4<br>IIV4-RIV4<br>IIV4-IIV4<br>0.007<br>0.0002</div>
</div>
<div class="page">
<h2>Page 9</h2>
<div class="figure">
<img src="figures/figure_p9_4ca7587d.png" alt="[FIGURE 1 - See figure_p9_4ca7587d.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p9_4ca7587d.png]</div>
</div>
<div class="text">years, it also signiﬁcantly increased the quantity of the total A(H3N2)<br>cell HA head binding antibodies (Fig. 4A, Fig. S1A). However, for<br>A(H1N1)pdm09 and B viruses, the difference in HI antibody versus the<br>otal HA head binding antibody levels among 4 vaccine groups was less<br>consistent suggesting that the magnitude of improvement differ</div>
<div class="text">IIV4 and ccIIV4 (15 µg HA/dose/strain). For A(H3N2), RIV4 vaccination<br>t<br>l i<br>d th<br>lit<br>f th f<br>ti<br>l<br>t<br>li i<br>tib d<br>Fig. 7 | Dynamics of proportion of participants with HI GMT egg/cell ratio ≥4<br>fold among seven repeat vaccination arms in Year 2. Proportions of Year 2<br>participants who had ≥4 -fold reduced titer to cell vaccine virus (egg/cell titer ratio)<br>at pre- and 1-month post-vaccination were presented for each vaccine component<br>among the seven Year 1-Year 2 vaccine arms. A: 18-44 years age group and B: 45−64</div>
<div class="text">have reported that Q223R egg-adapted change at the HA head domain<br>of A(H1N1)pdm09 virus can promote virus replication in eggs, alter<br>antigenicity and inﬂuence immune response37–42. In this study, 1-month<br>post-vaccination GMTs to both egg- and cell-propagated A(H1N1)<br>pdm09 vaccine viruses in year 1 were similar among the 4 vaccine</div>
<div class="text">The impact of egg-adaptation was the least profound on the<br>years age group. Fisher’s exact test (two-tailed) was performed for comparing<br>proportions of ≥4 -fold reduced titer to cell vaccine virus between pre- and<br>1-month post-vaccination in each vaccine group. P values noted on the corre-<br>sponding trend lines indicate statistically signiﬁcant difference of the proportions<br>between pre- and post-vaccination.</div>
</div>
<div class="page">
<h2>Page 10</h2>
<div class="figure">
<img src="figures/figure_p10_bc3b9c58.png" alt="[FIGURE 1 - See figure_p10_bc3b9c58.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p10_bc3b9c58.png]</div>
</div>
<div class="text">pre- and 1-month post-vaccination in 7 repeat vaccination arms. Antibody titers<br>from each of the 7 vaccine arms were presented as geometric mean titers (GMTs)<br>with 95% conﬁdence interval (CI) for combined 18−44 years and 45−64 years age<br>groups. Gray dots represented individual titers. ccIIV4-ccIIV4 (n = 20), ccIIV4-RIV4<br>(n = 22), RIV4-ccIIV4 (n = 16), RIV4-RIV4 (n = 16), IIV4-ccIIV4 (n = 22), IIV4-RIV4</div>
<div class="text">B/YAM<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>ELISA titers (Log2 sca<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>Fig. 8 | HA head and stalk binding antibody responses measured by ELISA at</div>
<div class="text">A(H1N1)pdm09<br>B/VIC<br>Day 0<br>1 m<br>400<br>800<br>1600<br>ELISA tit<br>Day 0<br>1 m<br>400<br>800<br>1600<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>51200<br>ELISA titers (Log2 scale)<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>51200<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>51200<br>ELISA titers (Log2 scale)<br>Day 0<br>1 m<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>51200<br>0.00</div>
<div class="text">A(H3N2)<br>A<br>Egg virus HA<br>Cell virus HA<br>3200<br>6400<br>12800<br>25600<br>51200<br>ers (Log2 scale)<br>3200<br>6400<br>12800<br>25600<br>51200<br>0.039</div>
<div class="text">0<br>1<br>2<br>RIV4-ccIIV4<br>RIV4-RIV4<br>IIV4-ccIIV4<br>IIV4-RIV4<br>IIV4-IIV4<br>H3 stalk<br>H1 stalk<br>Geometric mean fold<br>titers to HA stalk<br>within the same age group (A). One-way ANOVA corrected for multiple compar-<br>sons (Tukey’s test) was used to compare the GMTs of stalk binding antibody at<br>each time point among the 4 vaccine groups (C). One-way ANOVA nonparametri<br>Kruskal-Wallis test was used to compare the fold changes among the 4 vaccine<br>groups (B, D).Statistically signiﬁcant differences between groups are indicated by p<br>values on the horizontal bars (A, C). *In (C), paired t test (two-tailed) was used fo</div>
<div class="text">Day 0<br>1 m<br>200<br>400<br>800<br>1600<br>3200<br>6400<br>ELISA titers (Log2 scale)<br>IIV4-ccIIV4<br>IIV4-RIV4<br>IIV4-IIV4<br>ccIIV4-ccIIV4<br>ccIIV4-RIV4<br>RIV4-ccIIV4<br>RIV4-RIV4<br>*<br>*<br>*<br>*<br>Day 0<br>1 m<br>200<br>400<br>800<br>1600<br>3200<br>6400<br>12800<br>25600<br>ELISA titers (Log2 scale)<br>0.037<br>0.037<br>0.017<br>*<br>*<br>H3 stalk<br>H1 stalk<br>A <br>C<br>D</div>
<div class="text">B<br>0<br>1<br>2<br>3<br>4<br>ccIIV4-ccIIV4<br>ccIIV4-RIV4<br>RIV4-ccIIV4<br>RIV4-RIV4<br>IIV4-ccIIV4<br>IIV4-RIV4<br>IIV4-IIV4<br>H3 HA<br>H1 HA<br>B/VIC HA<br>B/YAM HA<br>Geometric mean ratio of  ELISA <br>titer egg/cell HA (95% CI)<br>ccIIV4-ccIIV4<br>ccIIV4-RIV4<br>RIV4-ccIIV4<br>RIV4-RIV4<br>IIV4-ccIIV4<br>IIV4-RIV4<br>IIV4-IIV4<br>Egg/cell HA ELISA ter rao (1m)</div>
</div>
<div class="page">
<h2>Page 11</h2>
<div class="title">None</div>
<div class="figure">
<img src="figures/table_p11_be884ade.png" alt="[TABLE 2 - See table_p11_be884ade.png]" style="max-width: 800px;">
<div class="figure-caption">[TABLE 2 - See table_p11_be884ade.png]</div>
</div>
<div class="text">blinding were previously described27–29. Participant characterisitcs in<br>year 1 are described in Table 2. During Year 1, HCP were stratiﬁed by two<br>age groups (18−44 years and 45−64 years) and randomized at 4:4:2:2</div>
<div class="title">United States during the Norther
2019−2020 (Year 2) inﬂuenza s</div>
<div class="text">ﬁndings from comparative immunogenicity studies and provide<br>additional information to identify optimal vaccination strategies to<br>prevent inﬂuenza.<br>Materials and methods<br>Study design<br>The original study was a randomized, open-label trial conducted in the<br>KPNW<br>49<br>40 45<br>37<br>136<br>48 51<br>26<br>Prior inﬂuenza vaccination history<br>Receipt of inﬂuenza vacicnes in<br>all the last 5 seasons<br>83<br>68 93<br>78<br>209<br>74<br>135<br>68<br>Prior season<br>vaccination(2017−2018)<br>108<br>89 104<br>87<br>245<br>87<br>176<br>89</div>
<div class="text">g<br>y<br>(11)<br>(11)<br>(11)<br>(12)<br>Age Group<br>18−44 years<br>57<br>47<br>55<br>46 135<br>48 99<br>50<br>45−64 years<br>65<br>53<br>65<br>54 148<br>52 99<br>50<br>Female<br>107<br>88<br>103<br>86 233<br>82 157<br>79<br>White<br>110<br>90 94<br>78<br>232<br>82 148<br>75<br>Hispanic<br>13<br>11<br>19<br>16<br>37<br>13<br>37<br>19<br>Site<br>BSWH<br>73<br>60 75<br>63 147<br>52 147<br>74</div>
<div class="title">n
%
n
%
n
%
n
Demographic characteristics</div>
<div class="text">Fluzone<br>IIV4<br>Fluarix<br>IIV4<br>ccIIV4<br>RIV4<br>n = 122<br>n = 120<br>n = 283<br>n = 198</div>
<div class="text">Statistical analyses<br>Geometric mean titers (GMTs) at day 0, 1-month and 6-months, geo-<br>metric mean fold rise (GMFR) of antibody titers at 1-month versus day<br>0, and geometric mean fold reduction of antibody titers at 6 months<br>versus 1-month were calculated per vaccine group. “GMT egg/cell titer<br>ratio” (ratio = GMT to egg-grown vaccine virus or rHA/GMT to cell-<br>grown vaccine virus or rHA) was calculated to quantify the difference<br>in antibody response to egg- versus corresponding cell-propagated<br>vaccine virus for each vaccine group. The proportion of participants</div>
<div class="text">(HRP) conjugated goat anti human pan immunoglobulin conjugate to<br>detect total binding antibodies. ELISA was performed based on pre-<br>viously described procedures46,47. The ELISA titers were determined as<br>the reciprocal of the highest dilution of serum samples that achieved an<br>optical density (OD) value of 0.2 or greater.<br>Sequence analyses<br>All the testing viruses used in this study were sequenced. Sequences<br>were analyzed against the sequences of candidate vaccine viruses (CVV)<br>of the study vaccines as deposited in Global Initiative on Sharing Avian<br>Inﬂuenza Data (GISAID) database by BioEdit version 7.0.9.0 (Table 1).</div>
<div class="text">0019/2016 viruses were tested in MN assays in year 1 using MDCK-SIAT1<br>cells using methods as previously described44. In Year 2, egg- and cell-<br>propagated A/Kansas/14/2017 viruses were tested by HI assays using<br>0.75% guinea pig erythrocytes in the presence of 20 nM oseltamivir.<br>Enzyme-linked immunosorbent assay (ELISA)<br>Twenty percent of participants were selected by random sampling from<br>each vaccine group and age strata (18−44 yrs and 45−64 yrs) in year 1<br>(n = 144) and year 2 (n = 140), the MN/HI antibody levels of the subset are<br>representative of the whole study populations in year 1 (Fig. S3) and year<br>2 (Fig. S4). These serum samples were tested by ELISA to evaluate the<br>total binding antibodies against 8 recombinant HA proteins (rHA from<br>both egg-and cell-propagated viruses of each of the 4 vaccine antigens),<br>and 2 rHA stalk proteins (A(H1N1)pdm09 HA stalk, and A(H3N2) HA<br>stalk). rHA from egg- and cell A/Michigan/45/2015 (H1N1)pdm09, rHA<br>head from egg- and cell- A/Singapore/INFIMH-16-0019/2016 (H3N2), B/<br>Colorado/06/2017 (B/Victoria), and B/Phuket/3073/2013 (B/Yamagata)<br>were tested with year 1 sera; rHA from egg- A/Brisbane/02/2018 (H1N1)<br>pdm09 and cell-A/Idaho/7/2018 (H1N1)pdm09, rHA head from egg- and<br>cell- A/Kansas/14/2017 (H3N2), egg- and cell- B/Colorado/06/2017 (B/<br>Victoria), egg- and cell-B/Phuket/3073/2013 (B/Yamagata) were tested<br>with year 2 sera. The puriﬁed and trimeric recombinant HA proteins<br>were expressed from the baculovirus system using the established<br>procedures45. For ELISA, rHA antigens were coated at 100 ng/well. Serum<br>samples were tested at an initial dilution of 1:400 followed by 2-fold<br>i l dil<br>i<br>A<br>ib di<br>d<br>d b<br>h<br>di h<br>id</div>
<div class="title">MDCK cells with</div>
<div class="text">y<br>p<br>y<br>y<br>assays in year 1 (the cell-grown vaccine antigen of the study year does<br>not hemagglutinate in the HI assays), and HI assays in year 2. Egg-grown<br>A(H3N2) viruses were propagated in 10-day-old embryonated chicken<br>eggs, cell-grown A(H3N2) viruses were propagated in stably transfected</div>
<div class="title">were tested in year 2</div>
<div class="text">p<br>p g<br>y<br>y<br>gg<br>g<br>A(H1N1)pdm09 and inﬂuenza B viruses were propagated in Madin-<br>Darby canine kidney (MDCK) cells. Inﬂuenza B antigens were ether-<br>treated prior to use in the HI assays. Egg- and cell (MDCK)-propagated<br>A/Michigan/45/2015 (H1N1)pdm09, B/Colorado/06/2017 (B/Victoria),<br>and B/Phuket/3073/2013 (B/Yamagata) viruses were tested in year 1,<br>Egg-propagated A/Brisbane/02/2018 (H1N1)pdm09, cell-propagated<br>A/Idaho/7/2018 (H1N1)pdm09, egg- and cell-propagated B/Colorado/<br>06/2017 (B/Victoria) and B/Phuket/3073/2013 (B/Yamagata) viruses</div>
</div>
<div class="page">
<h2>Page 12</h2>
<div class="text">8.<br>Dunkle, L. M. et al. Randomized comparison of immunogenicity and<br>safety of quadrivalent recombinant versus inactivated inﬂuenza<br>vaccine in healthy adults 18-49 years of age. J. Infect. Dis. 216,<br>1219–1226 (2017).<br>9.<br>Dunkle, L. M. et al. Safety and immunogenicity of a recombinant<br>inﬂuenza vaccine: a randomized trial. Pediatrics 141, e20173021 (2018).<br>10.<br>Nolan, T. et al. Efﬁcacy of a cell-culture-derived quadrivalent inﬂu-<br>enza vaccine in children. N. Engl. J. Med. 385, 1485–1495 (2021).<br>11.<br>Moehling, K. K. et al. A randomized controlled trial of antibody<br>response to 2018-19 cell-based vs. egg-based quadrivalent inacti-<br>vated inﬂuenza vaccine in children. Vaccine 38, 5171–5177 (2020).<br>12.<br>Hartvickson, R. et al. Non-inferiority of mammalian cell-derived<br>quadrivalent subunit inﬂuenza virus vaccines compared to trivalent</div>
<div class="title">vaccine e</div>
<div class="text">with MN or HI GMT egg/cell titer ratio ≥4 fold was calculated to<br>quantify the percent of participants with antibodies predominantly<br>targeting egg-adapted epitopes per vaccine group. One-way ANOVA<br>corrected for multiple comparisons (Tukey’s test) or nonparametric<br>Kruskal-Wallis test was used for multiple group comparison, two-tailed<br>paired t test was used to compare pre- and post-vaccination; two-tailed<br>unpaired t test was used to compare the post-vaccination titers<br>between IIV4-IIV4 (Fluzone) arm and each of the remaining 6 arms in<br>Year 2; Two-tailed Fisher’s exact test was used for comparing pro-<br>portions. P < 0.05 is considered statistically signiﬁcant. SAS 9.4 (SAS<br>Institute) and GraphPad Prism 8 (GraphPad Software, Inc.) were used<br>for statistical analyses.<br>Ethic review<br>The study protocol was reviewed and approved by the institutional<br>review boards (IRBs) of the study sites and the Centers for Disease<br>Control and Prevention. Informed consent was obtained from the par-<br>ticipants. This study is registered on ClinicalTrials.gov, NCT03722589.<br>Reporting summary<br>Further information on research design is available in the Nature<br>Portfolio Reporting Summary linked to this article.<br>Data availability<br>The data that support the ﬁndings of this study are included in the<br>manuscript, supplementary information, and the ﬁgshare repository<br>https://doi.org/10.6084/m9.ﬁgshare.22666231. Additional raw data<br>from the study are available from the corresponding author (mlevi-<br>ne@cdc.gov) upon request.<br>References<br>1.<br>Flannery, B. et al. Inﬂuenza vaccine effectiveness in the United<br>States during the 2016-2017 season. Clin. Infect. Dis. 68,<br>1798–1806 (2019).<br>2.<br>Levine, M. Z. et al. Antibodies Against Egg- and Cell-Grown Inﬂu-<br>enza A(H3N2) viruses in adults hospitalized during the 2017-2018<br>inﬂuenza season. J. Infect. Dis. 219, 1904–1912 (2019).<br>3.<br>Liu, F. et al. Age-speciﬁc effects of vaccine egg adaptation and<br>immune priming on A(H3N2) antibody responses following inﬂu-<br>enza vaccination. J. Clin. Investig. 131, e146138 (2021).<br>4.<br>Rolfes, M. A. et al. Effects of Inﬂuenza Vaccination in the United<br>States During the 2017-2018 Inﬂuenza Season. Clin. Infect. Dis. 69,<br>1845–1853 (2019).<br>5.<br>Wu,N.C.et al.Astructuralexplanationfortheloweffectivenessofthe<br>seasonal inﬂuenza H3N2 vaccine. PLoS Pathog. 13, e1006682 (2017).<br>6.<br>Zost, S. J. et al. Contemporary H3N2 inﬂuenza viruses have a gly-<br>cosylation site that alters binding of antibodies elicited by egg-<br>adapted vaccine strains. Proc. Natl. Acad. Sci. USA 114,<br>12578–12583 (2017).<br>7.<br>Barr, I. G. et al. Cell culture-derived inﬂuenza vaccines in the severe<br>2017-2018 epidemic season: a step towards improved inﬂuenza<br>13.<br>14.<br>15.<br>16.<br>17.<br>18.<br>19.<br>20.<br>21.<br>22.<br>23.<br>24.<br>25.<br>26.<br>27.</div>
</div>
<div class="page">
<h2>Page 13</h2>
<div class="text">systematic review and meta-analysis. Lancet Respir. Med. 11,<br>27–44 (2023).<br>34. Shaw, M. W. et al. Reappearance and global spread of variants of<br>inﬂuenza B/Victoria/2/87 lineage viruses in the 2000-2001 and<br>2001-2002 seasons. Virology 303, 1–8 (2002).<br>35. Saito, T. et al. Antigenic alteration of inﬂuenza B virus associated<br>with loss of a glycosylation site due to host-cell adaptation. J. Med.<br>Virol. 74, 336–343 (2004).<br>36. Robertson, J. S. et al. Alterations in the hemagglutinin associated<br>with adaptation of inﬂuenza B virus to growth in eggs. Virology 143,<br>166–174 (1985).<br>37. Raymond, D. D. et al. Inﬂuenza immunization elicits antibodies<br>speciﬁc for an egg-adapted vaccine strain. Nat. Med. 22,<br>1465–1469 (2016).<br>38. Liu, F. et al. Inﬂuence of immune priming and egg adaptation in the<br>vaccine on antibody responses to circulating A(H1N1)pdm09 viru-<br>ses after inﬂuenza vaccination in adults. J. Infect. Dis. 218,<br>1571–1581 (2018).<br>39. Koel, B. F. et al. Identiﬁcation of amino acid substitutions supporting<br>antigenic change of inﬂuenza A(H1N1)pdm09 viruses. J. Virol. 89,<br>3763–3775 (2015).<br>40. Koel, B. F. et al. Substitutions near the receptor binding site deter-<br>mine major antigenic change during inﬂuenza virus evolution. Sci-<br>ence 342, 976–979 (2013).<br>41.<br>Chen, Z. et al. Generation of live attenuated novel inﬂuenza virus A/<br>California/7/09 (H1N1) vaccines with high yield in embryonated<br>chicken eggs. J. Virol. 84, 44–51 (2010).<br>42. Caton, A. J., Brownlee, G. G., Yewdell, J. W. & Gerhard, W. The<br>antigenic structure of the inﬂuenza virus A/PR/8/34 hemagglutinin<br>(H1 subtype). Cell 31, 417–427 (1982).<br>43. Network WGIS. Manual for the laboratory diagnosis and virological<br>surveillance of inﬂuenza. https://iris.who.int/bitstream/handle/<br>10665/44518/9789241548090_eng.pdf?sequence=1 (2011).<br>44. Gross, F. L., Bai, Y., Jefferson, S., Holiday, C. & Levine, M. Z. Mea-<br>suring Inﬂuenza Neutralizing Antibody Responses to A(H3N2) Viru-<br>ses in Human Sera by Microneutralization Assays Using MDCK-SIAT1<br>Cells. J. Vis. Exp. 56448, https://doi.org/10.3791/56448 (2017).<br>45. Stevens, J. et al. Structure of the uncleaved human H1 hemagglu-<br>tinin from the extinct 1918 inﬂuenza virus. Science 303,<br>1866–1870 (2004).<br>46. Li, Z. N. et al. IgM, IgG, and IgA antibody responses to inﬂuenza<br>A(H1N1)pdm09 hemagglutinin in infected persons during the ﬁrst<br>wave of the 2009 pandemic in the United States. Clin. Vaccin.<br>Immunol. 21, 1054–1060 (2014).<br>47. Li, Z. N. et al. Serologic evidence of inﬂuenza A(H1N1)pdm09 virus<br>infection in northern sea otters. Emerg. Infect. Dis. 20, 915–917 (2014).<br>Acknowledgements<br>We thank the staff from Baylor Scott & White Health and Kaiser Perma-<br>nente Northwest for their participation and support of the study. We<br>Author contributions<br>M.Z.L., F.S.D., B.F., A.M.F., M.G.T., T.T., M.G. and A.L.N. were involved in<br>the conception and the design of the studies. F.L., F.L.G., S.J., K.M., H.G.,<br>M.G.W., L.J.E., L.G., S.S.K., S.S., S.G., performed the studies and acquired<br>the data. F.L. and S.J. analyzed the data. F.L. and M.Z.L. wrote the<br>manuscript. M.Z.L. supervised the study. All co-authors were involved in<br>manuscript preparation process for important intellectual content.<br>Competing interests<br>M.G.received funding from Pﬁzer for anunrelated educational grant and<br>Janssen for an unrelated study. A.L.N. received research funding from<br>Pﬁzer and Vir Biotechnology for unrelated studies. All other authors<br>declared no conﬂict of interest.<br>Additional information<br>Supplementary information The online version contains<br>supplementary material available at<br>https://doi.org/10.1038/s41467-023-44551-x.<br>Correspondence and requests for materials should be addressed to Min<br>Z. Levine.<br>Peer review information Nature Communications thanks Surender<br>Khurana and the other, anonymous, reviewer(s) for their contribution to<br>the peer review of this work.<br>Reprints and permissions information is available at<br>http://www.nature.com/reprints<br>Publisher’s note Springer Nature remains neutral with regard to jur-<br>isdictional claims in published maps and institutional afﬁliations.<br>Open Access This article is licensed under a Creative Commons<br>Attribution 4.0 International License, which permits use, sharing,<br>adaptation, distribution and reproduction in any medium or format, as<br>long as you give appropriate credit to the original author(s) and the<br>source, provide a link to the Creative Commons licence, and indicate if<br>changes were made. The images or other third party material in this<br>article are included in the article’s Creative Commons licence, unless<br>indicated otherwise in a credit line to the material. If material is not<br>included in the article’s Creative Commons licence and your intended<br>use is not permitted by statutory regulation or exceeds the permitted<br>use, you will need to obtain permission directly from the copyright<br>holder. To view a copy of this licence, visit http://creativecommons.org/<br>licenses/by/4.0/.<br>© This is a U.S. Government work and not under copyright protection in<br>the US; foreign copyright protection may apply 2024<br>1Inﬂuenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Baylor Scott & White Health, Temple, TX, USA. 3Baylor College of Medicine,<br>Temple, TX, USA. 4Texas A & M University, College of Medicine, Temple, TX, USA. 5Kaiser Permanente Northwest Center for Health Research, Portland,<br>OR, USA. 6Abt Associates, Atlanta, GA, USA.<br>e-mail: mlevine@cdc.gov</div>
<div class="text">States During the 2018 2019 Inﬂuenza Season. Clin. Infect. Dis. 71,<br>e368–e376 (2020).<br>32. Ramsay, L. C. et al. The impact of repeated vaccination on inﬂuenza<br>vaccine effectiveness: a systematic review and meta-analysis. BMC<br>CDC for providing the recombinant HA proteins. We also thank Makeda<br>Kay and Stacie Jefferson from inﬂuenza division of CDC for their assis-<br>tance with the study. Funding: This study was funded by the US Centers<br>for Disease Control and Prevention (contract 75D30118F02850). Dis-</div>
</div>
<div class="metadata">
<h3>Extraction Metadata</h3>
<p>Text blocks: 86</p>
<p>Figures/Tables: 10</p>
</div>

</body>
</html>
